Page last updated: 2024-10-29

nsc 664704 and Brain Neoplasms

nsc 664704 has been researched along with Brain Neoplasms in 1 studies

kenpaullone: inhibits CDK1/cyclin B; structure in first source
kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).

Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kitabayashi, T1
Dong, Y1
Furuta, T1
Sabit, H1
Jiapaer, S1
Zhang, J1
Zhang, G1
Hayashi, Y1
Kobayashi, M1
Domoto, T1
Minamoto, T1
Hirao, A1
Nakada, M1

Other Studies

1 other study available for nsc 664704 and Brain Neoplasms

ArticleYear
Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
    Scientific reports, 2019, 07-11, Volume: 9, Issue:1

    Topics: Animals; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dru

2019